Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice [0.03%]
阿特珠单抗联合贝伐珠单抗治疗日本不可切除肝细胞癌患者的初期真实世界经验
Yuka Hayakawa,Kaoru Tsuchiya,Masayuki Kurosaki et al.
Yuka Hayakawa et al.
Background: We aimed to investigate the efficacy and safety of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (u-HCC) based on whether they had previously received systemic th...
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study [0.03%]
口服XPO1抑制剂Selinexor联合卡铂和紫杉醇治疗晚期实体瘤患者的疗效：单中心、多组别Ib期研究结果
Kyaw Z Thein,Daniel D Karp,Apostolia Tsimberidou et al.
Kyaw Z Thein et al.
Background: Carboplatin and paclitaxel (CT) is one of the standard chemotherapy regimens used in various tumor types. Preclinical models have suggested that selinexor, a first-in-class oral potent selective inhibitor of n...
Tatsuya Ogimoto,Hironori Yoshida,Masanobu Mizuta et al.
Tatsuya Ogimoto et al.
Nivolumab, a programmed death 1 blockade drug, is used in various types of cancers and can cause a unique immune-related adverse event (irAE). Relapsing polychondritis (RP) is a rare autoimmune disease that mainly involves inflammation of t...
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study [0.03%]
在晚期癌症患者中对选择性蛋白激酶出口抑制剂进行一期试验时用支持性治疗预防恶心，呕吐和厌食：探索性研究
Rony Dev,Linda L Zhong,Abdulrazzak Zarifa et al.
Rony Dev et al.
Introduction: Clinical observations of cancer patients treated with selinexor have reported high incidence of nausea and anorexia. The study objective was to investigate the adoption of prophylactic olanzapine for the pre...
Modulation of peritumoral fibroblasts with a membrane-tethered tissue inhibitor of metalloproteinase (TIMP) for the elimination of cancer cells [0.03%]
用膜拴组织金属蛋白酶抑制剂（TIMP）调节肿瘤周边成纤维细胞以消除癌细胞
Yihe Zhang,Shiyu Liu,Bingjie Jiang et al.
Yihe Zhang et al.
Background: Peritumoral fibroblasts are key components of the tumor microenvironment. Through remodeling of the extracellular matrix (ECM) and secretion of pro-tumorigenic cytokines, peritumoral fibroblasts foster an immu...
A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target [0.03%]
胰腺癌中不同基因类群的综合分析：SIGLEC15可能是一个有前景的免疫治疗靶点
Ji-Li Xu,Yong Guo
Ji-Li Xu
Background: Pancreatic cancer (PC) is one of the most lethal cancer types with an extremely poor diagnosis and prognosis. This study aimed to comprehensively analyze the relationships between PC and different gene classes...
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies [0.03%]
口服VEGFR抑制剂西地拉尼布与口服MEK抑制剂司美替尼联用在晚期实体瘤患者中的I期研究
Joleen M Hubbard,Jun Yin,Erin L Schenk et al.
Joleen M Hubbard et al.
Purpose: Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple ...
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer [0.03%]
Kat2b是一个与免疫浸润相关的预后标志物，可预测非小细胞肺癌患者的免疫治疗反应
Xue Zhou,Ning Wang,Yuefeng Zhang et al.
Xue Zhou et al.
Background: Over the past few years, dramatic breakthroughs in the field of tumor immunotherapy with immune checkpoint inhibitors (ICIs) have made a therapeutic revolution for non-small cell lung cancer (NSCLC). While onl...
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer [0.03%]
每周纳米白蛋白结合型紫杉醇联合卡铂同步胸部放疗治疗不可手术的局部晚期非小细胞肺癌老年患者一期临床研究
Shota Omori,Hideyuki Harada,Keita Mori et al.
Shota Omori et al.
Few clinical studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiother...
Antineoplastic activity of products derived from cellulose-containing materials: levoglucosenone and structurally-related derivatives as new alternatives for breast cancer treatment [0.03%]
纤维素材料衍生的抗肿瘤活性物质：莱沃果糖酮和结构相关衍生物作为乳腺癌治疗的新方法
Damian Ignacio Delbart,German Francisco Giri,Agostina Cammarata et al.
Damian Ignacio Delbart et al.
Breast cancer is the leading cause of cancer death among women worldwide. For this reason, the development of new therapies is still essential. In this work we have analyzed the antitumor potential of levoglucosenone, a chiral building bloc...